XenTech presents 7 posters at AACR 2018


 

 

Abstract Number: 919

Endogenous STING inhibition induces breast cancer cell death

Date and Time: Sunday Apr 15, 2018; 1:00 PM – 5:00 PM

Location: Poster Section 41

Poster Board Number: 26

A current cancer immunotherapy strategy proposes the use of STING agonists to boost the patient’s immune system through the cytokine-mediated enhancement of tumor infiltration and killing by immune cells. Using breast cancer cell lines including those derived from patient-derived xenografts, we show that STING clustering at DNA breaks in the nucleus is a general feature of breast cancer cells exposed to genotoxic agents, and that the STING pathway is a cell-intrinsic mechanism of cell survival. This study points up potentially antagonistic effects of STING pathway manipulation in tumor control.

 

 

 

Abstract Number: 2147

Development of preclinical models to accelerate the identification of next generation treatments for patients with acquired resistance to targeted therapies

Date and Time: Monday Apr 16, 2018; 1:00 PM – 5:00 PM

Location: Poster Section 7

Poster Board Number: 2

Patients whose tumor harbor specific driver molecular alterations benefit from targeted therapies but responses are generally short-lived due to the emergence of adaptive/secondary resistance. The MATCH-R trial led by Gustave Roussy, Villejuif, France (NCT02517892) will enroll 600 patients treated with targeted therapies. Biopsies obtained from 300 patients at resistance will be used to develop PDX models. This first report features PDX models with acquired resistance to last-generation therapies such as osimertinib, erdafitinib or trametinib. The MATCH-R PDX platform is being regularly upgraded with new models, providing a unique resource to unravel the mechanisms involved in acquired resistance to targeted therapies and develop novel therapeutic strategies translating into increased patient survival.

 

 

 

Abstract Number2811

High IFN/STAT-related gene expression is associated with sensitivity to PARP inhibitors of triple negative breast cancer

Date and Time: Monday Apr 16, 2018; 1:00 PM – 5:00 PM

Location: Poster Section 37

Poster Board Number: 1

Pathogenic BRCA1/2 mutations and other genomic alterations are hallmarks of cancers with homologous recombination deficiency (HRD) that are more likely to be sensitive to PARP inhibitors (PARPi). However, these markers lack specificity as less than half of patients harboring BRCA-mutated or HRD-positive tumors are responsive to PARP inhibitors, and a number of tumors without BRCA1/2 mutations are responsive to PARPis. In vivo efficacy of PARPis was tested in a panel of 53 TNBC PDX models characterized for BRCA1/2 or HRD status and a gene expression classifier was built that improved the accuracy of the BRCA and HRD assays in predicting PARPi responsiveness.

Abstract Number4628

Tailoring personalized strategies for children with treatment-refractory liver cancer

Date and Time: Tuesday Apr 17, 2018; 1:00 PM – 5:00 PM

Location: Poster Section 29

Poster Board Number: 1

Hepatoblastoma (HB) is a rare paediatric tumor for which it is difficult to set up clinical trials. We developed a panel of 24 HB PDX models and 10 corresponding PDX-derived cell lines as a translational platform for the development of novel therapeutic options for children with HB. Here we show that volasertib, an inhibitor of the PLK1 oncogene that is overexpressed in HB, displays a good efficacy profile, comparable to that of the temozolomide/irinotecan combination.

 

Abstract Number: 5600

Establishment and characterization of a unique circulating tumor cells-derived xenograft (CDX) in prostate cancer

Date and Time: Wednesday, April 18; 8:00 AM-12:00 PM

Location: Poster Section 27

Poster Board Number: 3

We report the development of a unique PDX model from the CTCs of a patient with advanced prostate cancer (PCa). While demonstrating the tumorigenicity of CTCs from PCa, this CDX model represents a unique tool to identify clonal mutations associated with the tumor-initiating capacity of CTCs and explore the genetic and phenotypic basis of metastasis and drug resistance in advanced PCa.

 

Abstract Number: 1718

Tumor immune gene profile before and after various targeted therapies in NSCLC PDXs

Date and Time: Monday Apr 16, 2018; 8:00 AM – 12:00 AM

Location: Poster Section 32

Poster Board Number: 13

Using a panel of non-humanized NSCLC PDXs, we have identified specific tumor immune profiles and a set of genes involved in the response to targeted therapies. Pharmacodynamic analysis of immune markers reveals potential combinations of targeted therapies with immune checkpoints blockade that may have important translational value.

 

Abstract Number: 2597

Development and characterization of novel non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs)-derived xenograft (CDX) models

Date and Time: Monday Apr 16, 2018 1:00 PM – 5:00 PM

Location: Poster Section 25

Poster Board Number: 27

We describe the establishment and characterization of 4 CDX models from advanced NSCLC patients. This study revealed both similarities and differences between CDXs and their corresponding patient tumor biopsies. These NSCLC CDX models represent unique tools to identify clonal mutations associated with the tumor-initiating capacity of CTCs and explore the genetic and phenotypic basis of metastasis and drug resistance associated with advanced NSCLC.

 

The Match-R PDX project


XenTech launches a new line of PDX models of acquired resistance to last generation targeted therapies

 

Development of 75 PDX models from patients with acquired resistance to latest targeted drugs

A preclinical platform to identify resistance mechanisms and develop new therapeutic strategies

 

Background: Patients whose tumor harbor specific driver molecular alterations benefit from targeted therapies. These molecules have a good efficacy profile but patients’ responses are generally short-lived due to the emergence of adaptive/secondary resistance. Disposing of clinically relevant models to identify the resistance mechanisms at play and perform preclinical POC studies is critical to develop new therapeutic strategies translating into increased patient survival.

 

Outline:

The MATCH-R precision medicine trial led by Gustave Roussy (NCT02517892) will enroll 600 patients treated with targeted therapies in phase I/II studies between 2014 and 2020. Its main goal is to study the molecular evolution of tumors subjected to targeted therapies and developing acquired resistance.

Biopsies from progressing tumor lesions will be performed in 300 patients having developed resistance following initial response and used to generate PDX models that will be expanded under therapy to confirm their resistance status and molecularly characterized by WES and RNAseq.

 

Click images below for

Already available Models                                                                                                                                       Models in Development for 2018

XenTech wishes 2018


We wish you a Happy Holiday Season

&
Best wishes for the New Year !

 

4-9 December, 2017 | San Antonio | SABC Symposium


 

XenTech will attend to the 2017 San Antonio Breast Cancer Symposium.

We will talk about state-of-the-art experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, with international academicians and other private physicians and researchers.

 

We are looking forward to see you there !

 

To know more about SABCS2017, it’s here.

July 2017 | ITCC-P4 official launch


XenTech is proud to be part of the ITCC-P4, a new platform to accelerate drug development for children and adolescents dying of cancer.

It has been several years since XenTech developed pediatric PDX especially liver cancer PDX. Children and adolescents cancers need to be studied since the preclinical research aside from adult cancers. At XenTech, we strongly believe that strong partnerships with other specialists in the field is the key of a successfull child cancer research.

If you want to learn more about ITCC-P4, read the Press Release

26 – 30 October 2017 | Philadelphia, USA | AACR-NCI-EORTC Conference


 

The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics will be held at the Pennsylvania Convention Center in Philadelphia, Pennsylvania, from October 26-30, 2017 with exhibit dates on October 28-29.

We will be part of companies with the latest in products and services in laboratory and clinical research!

On this special occasion, we will be glad to talk about PDX & preclinical applications: meet us at booth# 310 !See you soon #aacrncieortc2017 !

Do you want to know more about this event ? Click here.

 

 

 

July 18-20 2017 | Boston,USA | Tumor Models Congress


Xentech is pleased to announce its participation to the Boston Tumor Models Congress in July 18-20, 2017.

Our business development team will be there to answer to your questions about XenTech Tumor Models! #TMB2017

Moreover, many interesting presentations to attend, if you want to know more about the agenda, go to the website.

April 1-5th, 2017 | Washington, USA | AACR Annual Meeting


 

XenTech will be attending the 2017 AACR annual meeting in Washington. Come and visit us at booth #343 and poster sessions !

 

Poster # 3856 : Identification of circulating tumour cells in breast cancer patient-derived xenograft models

Session Date and Time: Tuesday Apr 4, 2017 8:00 AM 12:00 PM

Poster # 4936 : Modelling clinical issues by using patient-derived xenografts: Evaluation of partial hepatectomy on hepatoblastoma intrahepatic and distant growth

Session Date and Time: Tuesday Apr 4, 2017 1:00 PM – 5:00 PM

Poster # 90 : STING colocalizes with gamma-H2AX upon treatment of breast cancer cells with genotoxics: A new role in DNA repair?

Session Date and Time: Tuesday Apr 4, 2017 1:00 PM – 5:00 PM

 

 

Right after the AACR meeting, we will be heading to Massachusetts from April, 6th until April, 12th. This could be a great opportunity for us to touch base and allow us to present you our most recent models and services.

If you are interested in hearing more about our PDX expertise, set up a meeting with our dedicated team:

See you soon #AACR17 !

March 20-22nd, 2017 | Barcelona, Spain | Bio Europe Spring


XenTech is pleased to attend to the 11th BIO Europe Spring event on March in Barcelona.

It is the perfect occasion to meet you and talk about your projects in preclinical development of anti cancer drugs.

More info about this partnering conference here.

To set up a meeting with our dedicated team, send us a request:See you soon #bioeuropespring2017 !

 

March 6-8th, 2017 | Paris | Targeted Anti-Cancer Therapies Congress


Meet us at the Targeted Anti-Cancer Therpies Congress in Paris. We will talk about new molecular targets and innovative cancer therapeutics in the early phases of clinical development, supplemented by associated translational research and drug development methodology.

Do you want to know more about this event ? See the official program.

At this occasion, we will be glad to meet you, send us a request :